Table 3.
Top 10 co-cited references.
| Rank | Title | Article type | Author | Year | Journal | Citation |
|---|---|---|---|---|---|---|
| 1 | Familial hypercholesterolemia is underdiagnosed and undertreated in the general population: guidance for clinicians to prevent coronary heart disease | Guideline | Børge G. Nordestgaard | 2013 | European Heart Journal | 438 |
| 2 | Evolocumab and clinical outcomes in patients with cardiovascular disease | Original article | Marc S. Sabatine | 2017 | N Engl J Med | 228 |
| 3 | Diagnostic yield and clinical utility of sequencing familial hypercholesterolemia genes in patients with severe hypercholesterolemia | Original article | Amit V Khera, Hong-Hee Won, Gina M Peloso |
2016 | J Am Coll Cardiol | 191 |
| 4 | Homozygous familial hypercholesterolemia: new insights and guidance for clinicians to improve detection and clinical management. A position paper from the Consensus Panel on Familial Hypercholesterolaemia of the European Atherosclerosis Society | Guideline | Marina Cuchel | 2014 | Eur Heart J | 190 |
| 5 | Efficacy and safety of alirocumab in reducing lipids and cardiovascular events | Original article | Jennifer G. Robinson | 2015 | N Engl J Med | 170 |
| 6 | Ezetimibe added to statin therapy after acute coronary syndromes | Original article | Christopher P. Cannon | 2015 | N Engl J Med | 129 |
| 7 | 2013 ACC/AHA Guideline on the treatment of blood cholesterol to reduce atherosclerotic cardiovascular risk in adults | Guideline | Neil J. Stone | 2014 | Circulation | 126 |
| 8 | Inhibition of PCSK9 with evolocumab in homozygous familial hypercholesterolemia (TESLA Part B): a randomized, double-blind, placebo-controlled trial | Original article | Frederick J Raal | 2014 | Lancet | 126 |
| 9 | Mutations causative of familial hypercholesterolemia: screening of 98 098 individuals from the Copenhagen General Population Study estimated a prevalence of 1 in 217 | Original article | Marianne Benn | 2016 | Eur Heart J | 126 |
| 10 | Low-density lipoproteins cause atherosclerotic cardiovascular disease. 1. Evidence from genetic, epidemiologic, and clinical studies. A consensus statement from the European Atherosclerosis Society Consensus Panel | Review | Brian A. Ference | 2017 | Eur Heart J | 126 |
| 11 | The agenda for familial hypercholesterolemia: a scientific statement from the American Heart Association | Review | Samuel S. Gidding | 2015 | Circulation | 126 |
AHA = American Heart Association, PCSK9 = proprotein convertase subtilisin/kexin 9.